Aim: Evaluate healthcare costs and utilization of treated diffuse large B-cell lymphoma (DLBCL) follicular (FL) patients. Materials & methods: Adults with newly diagnosed DLBCL FL between 1 January 2008 31 October 2015 were identified in the Optum™ claims database. Healthcare assessed from diagnosis date until end follow-up. Results: A total 1267 DLBCL- 1595 FL-treated patients identified. Mean per-patient, per-month cost during follow-up was US$11,890 for US$10,460 FL. decreased year to 2...

This retrospective claims database study examined healthcare utilization (HCU) and costs associated with acute myeloid leukemia (AML) in 237 elderly patients who received chemotherapy or a stem cell transplant (SCT) following AML diagnosis. Patients secondary were excluded. Over the entire follow-up period, 92.0% of had ≥1 inpatient admission; 85.7% AML-related admission, 42.6% non-AML-related admission. During admissions, 39.2% intensive care unit (ICU) 20.7% having ICU 27.8% Total mean...

Aim: To evaluate treatment patterns of diffuse large B-cell lymphoma (DLBCL). Patients & methods: First-line and relapsed/refractory survival outcomes following first-line therapy in adult patients newly diagnosed with DLBCL were evaluated. Results: A total 1436 initiated mainly received a combination regimen versus monotherapy (92.1 vs 7.9%). who older more comorbidities had shorter progression-free than receiving (median: 31.3 55.8 months). In the second-line setting (n = 164),...

Abstract Background Myelosuppression is a major dose‐limiting complication of chemotherapy for patients with extensive‐stage small cell lung cancer (ES‐SCLC). The objective was to describe the burden myelosuppression, treatment patterns, and supportive care use among ES‐SCLC treated in US community oncology setting. Methods This retrospective cohort study used structured electronic medical record (EMR) data from Florida Cancer Specialists & Research Institute between January 2013...

Background— Randomized trials show improved outcomes among acute coronary syndrome patients treated with bivalirudin. The objective of this analysis was to compare clinical and economic in ST-elevation myocardial infarction (STEMI) encountered routine practice undergoing primary percutaneous intervention (PPCI), bivalirudin or heparin+GP IIb/IIIa receptor inhibitor (heparin+GPI). Methods Results— STEMI admissions from January 1, 2004 through March 31, 2008 receiving PPCI heparin+GPI the...

To compare patient characteristics, rates, and costs of medically attended falls among patients with Parkinson's disease (PD) probable PD plus neurogenic orthostatic hypotension (PD + nOH).MarketScan Commercial Medicare Supplemental databases (January 1, 2009-December 31, 2013) were used to identify nOH patients. The first medical or prescription claim suggesting these diagnoses served as the index date. Baseline characteristics post-index all-cause fall-related healthcare utilization...

BackgroundFew studies have evaluated real-world treatment patterns and survival in follicular lymphoma (FL). This study these outcomes among newly diagnosed patients with FL routine clinical care.Patients MethodsA retrospective was conducted from Humedica, a large United States electronic medical record database, January 1, 2008 to July 31, 2015. Patients were followed initiation until death, loss follow-up, or end of (September 30, 2015). Treatment assessed the follow-up period....

Intensive treatment for newly diagnosed acute myelogenous leukemia (ND-AML) patients are reserved "fit" patients. While guidelines recommend evaluation of age, performance status and comorbidities, there is no consensus on the definition "fitness" or optimal therapy elderly AML This retrospective study evaluated characteristics survival outcomes 274 (age ≥60 years) with ND-AML treated 7 + 3 (cytarabine an anthracycline) vs. hypomethylating agents (HMAs). Most received (60.2%) HMAs (39.8%) in...

Droxidopa is approved for adult patients with symptomatic neurogenic orthostatic hypotension (nOH); there limited information regarding effects on symptoms, outcomes, and quality of life (QOL) beyond two weeks treatment.Examine the real-world experience taking droxidopa after six months treatment.This non-interventional, US-based, prospective cohort study utilized a pharmacy hub, identifying who recently started nOH treatment. Questionnaires fall frequency other patient-reported outcomes...

Aim: Forty percent of patients with higher-risk myelodysplastic syndromes (HR-MDS) transform to acute myeloid leukemia (AML). Materials & methods: This retrospective study assessed the impact HR-MDS transformation AML on OS in a 6-month landmark analysis and results were validated using time-varying analysis. Results: The rate was 26.9% at 1 year. Patients who transformed had higher risk death than did not (HR: 1.82; p: 0.0072) year 2.85; p < 0.0001). treated azacitidine decitabine...

Objective:To examine economic consequences related to rehospitalization following initial acute coronary syndrome (ACS) treatment in United States managed care settings.Study design:Retrospective observational studies.Research design and methods:Retrospective studies were conducted on two populations medical encounter insurance claims charges for ACS-related rehospitalizations an index hospitalization new onset ACS (2002–2007). All adjusted year 2007 Dollars (USDs).Main outcome measures:The...

Objective:To study physician and patient perceptions of moderate-to-severe chronic pain its management with oral opioids.Methods:Two separate surveys were developed administered to one two respective groups: patients physicians. All participants recruited from a pool individuals who had previously agreed participate in market research. Survey questions addressed the impact various factors (e.g., quality life indicators, potential for opioid addiction, side-effects) on decision making,...

Significant clinical burden is associated with higher-risk myelodysplastic syndromes (HR-MDS); however, the economic has not been fully examined. We examined cost of care and healthcare utilization (HCU) in HR-MDS patients engaged routine United States (US).Adult US diagnosed from 1/1/2008 to 10/31/2015 were identified Optum database. Patients followed until death, progression acute myeloid leukemia (AML), end enrollment, or study (12/31/2015). Myelodysplastic syndrome (MDS)-related...

To characterize newly diagnosed primary open-angle glaucoma (OAG) patients and to describe their treatment journey in United States clinical practice according the use of topical therapy, laser trabeculoplasty, surgical procedures. Retrospective claims database study. Patients with at least 2 diagnoses OAG 7 days or more apart within 1 year, first (index) diagnosis 2010, 30 months continuous enrollment before index no medication (exception for ocular hypertension diagnosis), 48 enrollment....

BACKGROUND: Lupus nephritis (LN) is a common and severe complication of systemic lupus erythematosus (SLE), with approximately 40% patients SLE developing LN. Even treatment, 10%-30% will progress to end-stage renal disease (ESRD). Although many studies have assessed the clinical value low activity in LN, economic implications are less defined. OBJECTIVE: To evaluate treatment utilization health care costs associated active disease, activity, ESRD METHODS: A retrospective analysis Optum...

Objective: To evaluate the association between adherence to antidepressants and an effect on clinical outcomes healthcare costs in patients with major depressive disorder (MDD) comorbid type 2 diabetes (T2D).Methods: This retrospective study used MarketScan claims data from January 2012 March 2014. Study entry was first claim for antidepressant a diagnosis code MDD T2D prior 6 months. Adherence persistence therapy 180 days were defined as medication possession ratio (MPR) ≥ 80% length of...

Objectives: To evaluate the association between discontinuation of clopidogrel therapy and risk acute myocardial infarction (AMI) hospitalization or cardiac revascularization in a nationally-representative patient population following for an AMI coronary stent insertion.Research design methods: This observational cohort study was performed using data on patients from PharMetrics Anonymous Patient-Centric Database who were hospitalized insertion subsequently treated with clopidogrel. Cox...

Background: Lennox-Gastaut syndrome (LGS) is a severe form of childhood-onset epilepsy associated with serious injuries due to frequent and seizures. Of the antiepileptic drugs (AEDs) approved for LGS, clobazam more recent market entrant, having been in October 2011. Recent AED budget impact cost-effectiveness analyses LGS suggest that adding health plan formulary may result decreased medical costs; however, research on clinical economic outcomes treatment patterns these treatments limited....

Background: Atherothrombosis is a systemic disease that may manifest as acute ischemic events in multiple vascular beds. Patients who have experienced an atherothrombosis-related event 1 bed are at risk for developing other Antiplatelet therapy demands understanding of the balance between arterial thrombosis benefit and adverse risk. Clinical trials indicate dual antiplatelet with aspirin newer thienopyridines increases bleeding patients coronary syndromes (ACS) prior cerebrovascular events....